Erik Berger, MD
Sports Medicine · Soldotna, AKNPI 1003120502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $683 and has fallen 80.4% since, to $134 in 2022.
Across 75 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$255
- AstraZeneca$195
- Novo Nordisk$102
- Lilly USA, LLC$98
- Amarin Pharma, Inc.$85
- Johnson & Johnson$68
- plus $551 from 17 others
What the payments were for
- Food & beverage$1,354100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 6 | $255 |
| AstraZeneca | 14 | $195 |
| Novo Nordisk | 7 | $102 |
| Lilly USA, LLC | 7 | $98 |
| Amarin Pharma, Inc. | 4 | $85 |
| Johnson & Johnson | 4 | $68 |
| Merck | 4 | $57 |
| Pfizer | 4 | $56 |
| Arbor Pharmaceuticals, Inc. | 2 | $54 |
| Boehringer Ingelheim | 2 | $53 |
| Abbott | 3 | $51 |
| GSK | 4 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Astellas Pharma US Inc | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
Too few sports medicine providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $120,611 |
| JardianceEmpagliflozin | 75 | $104,834 |
| OzempicSemaglutide | 60 | $92,709 |
| XareltoRivaroxaban | 26 | $34,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,331 |
| MounjaroTirzepatide | 15 | $19,898 |
| JanuviaSitagliptin Phosphate | 15 | $16,288 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $11,504 |
| LinzessLinaclotide | 14 | $9,734 |
| Levothyroxine Sodium | 301 | $3,283 |
| Atorvastatin Calcium | 319 | $3,144 |
| Losartan Potassium | 263 | $2,809 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $2,687 |
| Lidocaine | 11 | $2,364 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $120,611119 claims |
| Boehringer IngelheimJardiance | $53 | $104,83475 claims |
| Novo NordiskOzempic | $102 | $92,70960 claims |
| Johnson & JohnsonXarelto | $68 | $34,81826 claims |
| GSKTrelegy Ellipta | $48 | $21,33116 claims |
| Lilly USA, LLCMounjaro | $98 | $19,89815 claims |
| MerckJanuvia | $57 | $16,28815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sports medicine providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other sports medicine in Soldotna
- Herbert BoteSoldotna$2K
- Erik MooreAnchorage$29K
- Jackson StaggersAnchorage$24K
- Mark WadeFairbanks$7K
- James AlexAnchorage$1K
- Elisha PowellAnchorage$1K
- Jared KirkhamAnchorage$562
- Nancy GreenwellAnchorage$484
- Jeffrey MooreAnchorage$454
- Christina DarbyAnchorage$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.